Safety and Treatment Continuity of Switching between CDK4/6 Inhibitors for Metastatic Breast Cancer due to Adverse Events: An Exploratory Single-Center Study in Japan

Oncology (Switzerland) · Published 2025-10-03 · DOI 10.1159/000548801

Authors being retrieved — see the publisher record. https://doi.org/10.1159/000548801

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2025

Related articles